AI to Accelerate the Future of Pancreatic Cancer Prevention/Care
Medical use of AI increases every day, and in the future, will be exponentially greater and many forms of treatment will be improved, according to Russell C. Langan, MD, FACS, FSSO.
Ablation Plus Intra-tumoral Therapy May Enhance Immune Responses in Tumors
Performing ablation and injecting tumor sites with immunotherapy may be “synergistic”, according to Jason R. Williams, MD, DABR.
Tislelizumab/Chemo Approved by European Commission For ESCC/GEJ
The European Commission has approved tislelizumab plus chemotherapy as treatment for patients with esophageal and gastric or GEJ cancer.
Lung Cancer Survival Improves Despite Biomarker Testing and Screening Gaps
Despite gaps in biomarker testing accessibility, the lung cancer survival rate has improved by 26% over the last 5 years.
New Therapies Shed Light on RAS-Mutated Pancreatic Cancer Management
Shubham Pant, MD, MBBS, highlights an “exciting time” in the treatment of patients with RAS-mutated pancreatic cancer.
Spreading Greater CAR T-Cell Therapy Education in the Community Setting
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
AI Software Learns to Identify Pancreatic Cancer Vs Cysts
A computational linguistics model designed to locate pancreatic cysts that started to locate pancreatic cancer has the potential to lead to more efficient treatment.
Tiragolumab/Atezolizumab Does Not Meet OS End Point in Metastatic NSCLC
Tiragolumab with atezolizumab, when compared with placebo with atezolizumab, failed to reach its overall survival end point in patients with NSCLC.
Onvansertib Combo Shows Significant Efficacy in KRAS+ Colorectal Cancer
For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.
The Effect of Multidisciplinary Teams for Advancing Research in NETs
Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.
Capivasertib Combo Significantly Improves rPFS in PTEN-Deficient HSPC
Data show an early trend towards improved overall survival with capivasertib plus abiraterone and androgen deprivation therapy in CAPItello-281.
Bridging Racial and Ethnic Minority Disparities in Pancreatic Cyst Surveillance
A computational linguistics model has mitigated disparities in surveillance of the pancreas that primarily affected racial and ethnic minorities.
SPM AE Incidence After CAR T-Cell Therapy in Lymphoma and Myeloma
Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab vs lenalidomide alone as post-transplant maintenance therapy for patients with newly diagnosed multiple myeloma.
Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells
Researchers at SickKids Hospital and McMaster University have developed a novel CAR T-cell therapy targeting ROBO1 for the treatment of recurrent glioblastoma.
Belantamab Mafodotin Combos Accepted for Review by FDA in Multiple Myeloma
A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.
Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer
Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.
Leveraging Community Setting Multidisciplinary Care in Pancreatic Cancer
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Adapting a Computation Linguistics Model to Surveil for Pancreatic Cancer
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Advancing Surgical Techniques in Neuroendocrine Tumors
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Building Upon an “Era of Therapeutic Refinement” in Pancreatic Cancer
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
VIOLETTE Trial Shows Precise Planning in Prostate Cancer Microwave Ablation
The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.
FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma
Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.
Pancreatic Cancer Incidence Has Risen, Yet Survival Outcomes Have Improved
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.
FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer
Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.
Multiple Myeloma Experts Face Off on Sequencing Therapy Options
Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.
Lung Cancer Home Health Screening Tools May Aid in Triaging LDCT+ Patients
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer
Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.
